MetaVia Inc. (NASDAQ:MTVA – Free Report) – Equities research analysts at HC Wainwright issued their FY2024 EPS estimates for MetaVia in a report issued on Monday, December 30th. HC Wainwright analyst E. Arce expects that the company will earn ($3.87) per share for the year. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($3.91) per share. HC Wainwright also issued estimates for MetaVia’s Q1 2025 earnings at ($0.65) EPS, Q2 2025 earnings at ($0.57) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.65) EPS, FY2027 earnings at ($4.27) EPS and FY2028 earnings at ($4.58) EPS.
MetaVia Trading Up 2.5 %
MTVA opened at $2.03 on Tuesday. MetaVia has a 52-week low of $1.51 and a 52-week high of $6.75.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
Further Reading
- Five stocks we like better than MetaVia
- Best Aerospace Stocks Investing
- 3 Stocks Helping to Bring AI to Healthcare
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- Stock Analyst Ratings and Canadian Analyst Ratings
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
